Cargando…

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model

Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor efficacy of radium-223, enzalutamide, and their combination in the intrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suominen, Mari I., Knuuttila, Matias, Schatz, Christoph A., Schlicker, Andreas, Vääräniemi, Jukka, Sjöholm, Birgitta, Alhoniemi, Esa, Haendler, Bernard, Mumberg, Dominik, Käkönen, Sanna-Maria, Scholz, Arne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916479/ https://www.ncbi.nlm.nih.gov/pubmed/36768509 http://dx.doi.org/10.3390/ijms24032189

Ejemplares similares

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2023)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2021)

The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
por: Suominen, Mari I., et al.
Publicado: (2019)

STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide
por: Rocha, Sandra M., et al.
Publicado: (2023)

ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors
por: Gustavsson, Heléne, et al.
Publicado: (2010)

Role of Testosterone Levels on the Combinatorial Effect of Boswellia serrata Extract and Enzalutamide on Androgen Dependent LNCaP Cells and in Patient Derived Cells
por: Pillai, Prathesha, et al.
Publicado: (2021)

Corrigendum to Role of Testosterone Levels on the Combinatorial Effect of Boswellia serrata Extract and Enzalutamide on Androgen Dependent LNCaP Cells and in Patient Derived Cells
Publicado: (2021)

Apogossypolone inhibits the proliferation of LNCaP cells in vitro and in vivo
por: ZHANG, XIANQING, et al.
Publicado: (2014)

Apogossypolone inhibits the proliferation of LNCaP cells in vitro and in vivo
por: Zhang, Xianqing, et al.
Publicado: (2018)

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer
por: Alibhai, Shabbir M. H., et al.
Publicado: (2021)

Calcitriol and TO-901317 Interact in Human Prostate Cancer LNCaP Cells
por: Wang, Jing-Huan, et al.
Publicado: (2008)

Alteration of Androgen Receptor Protein Stability by Triptolide in LNCaP Cells
por: Li, Wei, et al.
Publicado: (2018)

URG11 promotes proliferation and induced apoptosis of LNCaP cells
por: Sun, Chenmin, et al.
Publicado: (2019)

Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor Angiogenesis
por: Tsui, Paulus, et al.
Publicado: (2005)

Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells
por: Lee, Myoung-Sun, et al.
Publicado: (2016)

Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase
por: Yu, Pan, et al.
Publicado: (2017)

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study
por: McDermott, Raymond S., et al.
Publicado: (2021)

Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN
por: LIU, JUN, et al.
Publicado: (2014)

Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells
por: Cui, Luwei, et al.
Publicado: (2019)

Valproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell Survival
por: Giordano, Francesca, et al.
Publicado: (2019)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells
por: Ortel, B, et al.
Publicado: (2002)

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.
por: Wolf, D. A., et al.
Publicado: (1991)

LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer
por: Romanuik, Tammy L, et al.
Publicado: (2010)

Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment
por: Sieh, Shirly, et al.
Publicado: (2012)

EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells
por: CHEN, PEIJIE, et al.
Publicado: (2014)

Effect of curcumin on the interaction between androgen receptor and Wnt/β-catenin in LNCaP xenografts
por: Hong, Jeong Hee, et al.
Publicado: (2015)

MiR‐145 affected the circular RNA expression in prostate cancer LNCaP cells
por: He, Jin‐Hua, et al.
Publicado: (2018)

Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP
por: Sohn, Hong Moon, et al.
Publicado: (2019)

Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence
por: Dahl, Haley C., et al.
Publicado: (2020)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
por: Chen, Hao Xiang, et al.
Publicado: (2023)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Current approaches to incorporation of radium-223 in clinical practice
por: Parker, Chris, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3bh234djl3t12msgiao80p3s4k